West Pharmaceutical Services, Inc.'s Q2 results highlight growth driven by GLP-1 drugs and high-value products. Click for WST ...

Q2 2025 Earnings Call Transcript July 24, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported EPS ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Key Points - Adjusted EPS was $1.84 in Q2 FY2025, beating the $1.51 estimate by 21.9%, and GAAP revenue exceeded expectations by $40.4 million. Proprietary Products sales rose 10.7%, driven by strong ...

Discover West Pharma's robust Q2 2025 performance with 6.8% organic sales growth! Learn about raised guidance, high-margin gains, & GLP-1 market ...

TWG Announces Entry into a Memorandum of Understanding with Chinese Pharmaceutical Group for Injection of Pet Pharmaceutical Products Business ...

Shareholders of West Pharmaceutical Services, Inc. (Symbol: WST) looking to boost their income beyond the stock's 0.4% annualized dividend yield can sell the December covered call at the $250 ...

Brasada Capital Management, an investment management company, released its Q2 2025 investor letter. A copy of the letter can be downloaded here. This year’s financial markets have been highly volatile ...

The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and cluster headaches in adults, Amneal Pharmaceuticals announced Thursday.